Top Markets
#1 Helium Helium +110.72%
#2 MowCat MowCat +83.79%
#3 Seeker Seeker +72.11%
#4 AI XOVIA AI XOVIA +52.42%
#5 UnifAI Network UnifAI Network +33.65%
#6 Pons Pons +30.52%
#7 Tensor Tensor +26.60%
#8 TENDIES TENDIES +25.33%
#9 pipedog pipedog +22.04%
#10 Zylo Ecosystem Zylo Ecosystem +21.96%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Bright Minds Biosciences Inc. Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc.

DRUG
Rank in Stocks #11319
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics... Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Share Price
$73.12
Last synced: 2026-08-28
Market Cap
$715.61M
Change (1 day)
-1.90%
Change (1 year)
88.01%
Country
US
Trade Bright Minds Biosciences Inc. (DRUG)

Category

Healthcare
P/E ratio for Bright Minds Biosciences Inc. (DRUG)
P/E ratio as of 2026 TTM: 0
According to Bright Minds Biosciences Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Bright Minds Biosciences Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.